BOW Group Closes Series B Funding
The BOW Group announces today that it has closed its series B funding, led by PM Equity Partner (PMEP) and NextStage, the investment company listed on the Euronext Paris regulated exchange, NextStage, also participated in the financing round. BOW (Be Over the World) Group is a fast growing and consumer driven Internet-Of-Things (IOT) specialist, operating worldwide in the wearables, connected vehicles and smart home markets with 3 distinctive brands MyKronoz, RoadEyes and Deconnect.
“This new round of funding will enable us to expand our international presence to 100 countries by 2018 and to consolidate our leadership position in Europe while accelerating the development of innovative products and services within the IOT space. These investments will allow us to take the steps needed to fulfill our ambition to become a billion-dollar company in the next 5 years,” says Boris Brault, Chairman and CEO of BOW Group. Mr. Brault remains BOW’s majority shareholder.
Since its 2015 €10 million series A financing led by NextStage, BOW Group has demonstrated strong growth and profitable operations. BOW has over the last few years gained significant expertise in developing and launching IOT products through digital marketing and community engagement. Fueled by ambition and innovative vision, BOW Group has proven its ability to conquer new markets through a bold and winning commercial strategy combining traditional retail and digital channels. BOW has today sold more than 2.5 million devices.
The Swiss wearable brand MyKronoz is a strong asset of BOW Group. MyKronoz has in less than 4 years, established itself as a fierce challenger to both tech and traditional watchmakers, and is now considered one of the most promising startups in the smartwatch industry.
“Having backed BOW Group from its early beginning and helped them structure the 3 companies, we are proudly witnessing their ability to deliver innovations and scale up their business to compete in this fast-moving landscape. The Internet of Things market is set to hit $267B by 2020, and we are confident to be in an even stronger position today to take part, together, in this revolution,” says Nicolas de Saint Etienne, BOW Board member and Managing Partner at NextStageAM.
About BOW: BOW (Be Over the World) Group is a fast-growing and
consumer-driven IOT specialist, operating worldwide in the wearables,
connected vehicles and smart home markets with 3 distinctive brands MyKronoz,
Among its recent successes, there is the launch of ZeTime, MyKronoz’s newest unique hybrid smartwatch introduced onto online crowdfunding platforms. With over $6,000,000 raised and goods already shipped out to more than 30,000 backers, ZeTime became the biggest 2017 project on Kickstarter and Indiegogo, and the largest one ever from a European company.
In addition, MyKronoz, with its Swiss DNA and unique position of delivering stylish wearable devices at an affordable price, ranks as the best-selling IOT brand within the retail network of the leading French telecom operator Orange, boosting its ambition to duplicate this commercial success to many more mobile carriers around the world. More recently, MyKronoz has been selected by Amazon to join their Launchpad program, and is pleased to be considered as one of the strategic wearable brands by the world’s leading ecommerce platform.
NextStage is an investment platform created in March 2015 and listed on the Euronext Paris market (Compartment C) since December 2016. As of June 30, 2017, its Adjusted Net Asset Value represents €160.4 million. NextStage specialises in Medium-Sized Companies (MSCs), which allows access to an unlisted and often inaccessible class of assets that drives growth and performance. It invests in equity with little or no leverage over an unlimited time frame to provide funding for the growth of MSCs, alongside visionary entrepreneurs. NextStage is backed by the know-how and stability of the asset management firm NextStage AM, which was founded in 2002. NextStage has already closed twelve investment transactions (as of September 30, 2017) since its inception.www.nextstage.com/sca.
About PM Equity Partner:
PM Equity Partner is the corporate venture fund of Philip Morris International. For more information see www.pmequitypartner.com.
For information about PMI, see www.pmi.com and www.pmiscience.com
Chief Marketing Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33 | Pressemelding
Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55 | Pressemelding
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk
Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl
Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00 | Pressemelding
Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di
FCC Grants LeoSat U.S. Market Access16.11.2018 06:00 | Pressemelding
LeoSat Enterprises, the dynamic young company which is launching a unique new data network comprised of a constellation of up to 108 low-earth-orbit communications satellites, has been awarded the authority by the U.S. Federal Communications Commission (FCC) to provide NGSO (non-geostationary satellite orbit) services in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005890/en/ LeoSat's Global Business Backbone in Space (Graphic: Business Wire) The increasing demand for business connectivity and with it, the need to move large quantities of data quickly and securely around the world, is fast outpacing the infrastructure in place to carry it. Existing networks are already carrying more than 1 Zeta Byte of traffic globally and this is set to grow exponentially. The FCC market access grant will allow LeoSat to address currently unmet demand for high-bandwidth, low-latency, high-security data transmissio